SELLAS Life Sciences (SLS) Stock: What Does The Future Look Like?

11:40 am ET, 03 Apr 2018

For the latest news on SELLAS Life Sciences (NASDAQ: SLS), visit Finstead and type “SLS news”.  

SELLAS Life Sciences' remarkable positive results from its Phase 2b clinical trial for the prevention of cancer recurrence caused a significant surge in its stock price by more than 20% earlier in today’s trading.

Sellas has a lot of potential because of its cancer vaccine. 

However, no major analyst covers the company, and very little is known about what the future might look like.  

SELLAS is a biopharmaceutical that concentrates on developing cancer immunotherapies for various cancer indications. Its market cap is now around $40 Million (visit Finstead and type “SLS market cap”).

The clinical trial involved a combination of Roche's Herceptin (trastuzumab) and NeuVax (nelipepimut-S) in breast cancer patients. An improvement in the disease-free survival was noticed after administering the patients with Herceptin + NeuVax for 19 months.

A 70% decrease in the chances of cancer recurrence with respect to a control group was observed among the triple-negative breast cancer (TNBC) patients. There was a 74% cancer recurrence versus the control group among those who did not receive the hormonal therapy.

The company has created a cancer immunotherapeutic agent that can effectively treat hematologic cancers and solid tumor indications, which includes acute myeloid leukemia, malignant pleural mesothelioma, multiple myeloma, ovarian cancer, immune combo, and chronic myelogenous leukemia. This agent is Galinpepimut-S, which is used for its lead products.

The company has further plans for defining a developmental and regulatory path.

Disclaimer: The news article above expresses the author’s opinion about the topic of the article. We strongly advise you not to base your investment decisions just on this article alone. If you’d like to become a writer for Finny Bites, please send us an email at hi@askfinny.com.

SELLAS Life Sciences Group, Inc. (SLS) Stock Guide

Updated at: 2:23 am ET, 13 Jul 2020

Before we start: if you're looking for SLS stock price, you can quickly find it out by visiting Finny and typing "SLS quote". If you're looking for a quick scoop on SLS stock (chart, price target, market cap, news and buy or sell analysis), go to Finny and look for "SLS". You'll get all this info in one place. Or you can just type "SLS news" to get the latest stock news.

Looking to buy or sell SELLAS Life Sciences Group, Inc. (SLS)? Interested in getting the full scoop on SLS, including earnings and dividends, stock forecast, buy or sell analysis and key stats? If so, you came to the right place.

In this SLS stock guide, we'll address key questions about SLS, above and beyond what you can find on Yahoo Finance, Zacks, MarketWatch or Morningstar.

Here is what you'll be able to find in this guide:

Earnings and Dividends: earnings, earnings date, dividend rate and dividend yield;
Analysis: Finny Score and buy or sell analysis;
Key Stats: revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio, industry, sector, and number of employees.

And here is the list of questions we'll answer:
1. What are SLS earnings?
2. When is SLS earnings date?
3. SLS buy or sell? What is SLS Finny Score?
4. What are the reasons to buy SLS? Why should I buy SLS stock?
5. What are the reasons to sell SLS? Why should I sell SLS stock?
6. What are SLS key stats: revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio industry, sector, and number of employees?

So let's start. Scroll down to the question that interests you the most.

Earnings and Dividends

1. What are SLS earnings?

SLS trailing 12-month earnings per share (EPS) is -$10.92.

2. When is SLS earnings date?

SLS earnings date is May 14, 2020.

Analysis

3. SLS buy or sell? What is SLS Finny Score?

#{finnyScore:null}Our quantitative analysis shows 2 reasons to buy and 0 reasons to sell SLS. SLS doesn’t have an assigned Finny Score, because we don’t have sufficient data points to score the stock.

4. What are the reasons to buy SLS? Why should I buy SLS stock?

Here are the reasons to buy SLS stock:

  • SLS average analyst price target ($8.50) is above its current price ($2.97). See SLS price target chart.
  • SLS cash to debt ratio is 33.53, higher than the average industry (0.16) and sector (0.16) cash to debt ratio. See SLS cash to debt chart.

5. What are the reasons to sell SLS? Why should I sell SLS stock?

We can’t think of any good reason to sell this stock, which doesn’t mean they don’t exist.

Key Stats

6. What are SLS key stats : revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio industry, sector, and number of employees?

Let's look at the key statistics for SLS:

Metrics SLS
Price $3.47
Average Price Target / Upside $8.50 / 144.96%
Average Analyst Rating N/A
Forward Dividend Yield 0.00%
Industry Biotechnology
Sector Healthcare
Number of Employees 14
Market Cap $19.28M
Forward P/E Ratio -3.93
Price/Book Ratio N/A
Revenue (TTM) N/A
YoY Quarterly Revenue Growth N/A
Profit Margin 0.00%

If you liked this analysis, check out Stock Guides for other stocks.

Disclaimer: The news article above expresses the author’s opinion about the topic of the article. We strongly advise you not to base your investment decisions just on this article alone. If you’d like to become a writer for Finny Bites, please send us an email at hi@askfinny.com.

Use Finny to ask any finance or investment question. Big or small. Personal or general.
Follow Us